thyssenkrupp nucera AG & Co. KGaA (XETRA: NCH2) told the market on the evening of 11 August 2026 that it will stop building its own capacity to mass produce Solid Oxide Electrolysis Cell stacks, and that the decision forces down its earnings guidance for the 2025/26 financial year. The notice went out at 18:59 CET/CEST as a disclosure of inside information under Article 17 of Regulation (EU) No 596/2014, the form German issuers use when a decision cannot wait for a scheduled results date. The person named as making the notification was Dr. Hendrik Finger, the company’s Head of Investor Relations.
The Dortmund company builds electrolysis plants for green hydrogen and chlor-alkali production. Its shares trade on the Regulated Market in Frankfurt in the Prime Standard segment, and on the Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart and Tradegate, under ISIN DE000NCA0001.
What the company changed
The SOEC decision follows what thyssenkrupp nucera described as a comprehensive strategic review of market readiness, investment requirements and economic prospects. Ending the programme produces negative one-off EBIT effects of approximately EUR 30 million, which the company said come primarily from an impairment of the pilot plant and of capitalised development costs. Those charges land in the Green Hydrogen segment in the fourth quarter of the current financial year. From 2026/27 the company expects the reverse effect: lower SOEC spending worth an improvement of up to EUR 10 million in EBIT and approximately EUR 20 million in cash flow each year.
Two sets of numbers moved. Segment EBIT for Green Hydrogen is now guided to a range of EUR -155 million to EUR -135 million for 2025/26, against a previous range of EUR -125 million to EUR -90 million and an actual figure of EUR -56 million in 2024/25. Green Hydrogen sales were cut to EUR 100 million to EUR 130 million from EUR 120 million to EUR 170 million, after EUR 459 million in the prior year.
At group level, EBIT is now expected between EUR -105 million and EUR -75 million, where the earlier guidance was EUR -80 million to EUR -30 million. The group reported EBIT of EUR 2 million in 2024/25. Group sales guidance was narrowed rather than cut, to EUR 450 million to EUR 500 million from EUR 450 million to EUR 550 million, against EUR 845 million a year earlier. Order intake guidance was reduced at the top end only, to EUR 550 million to EUR 670 million from EUR 550 million to EUR 850 million, after EUR 348 million in 2024/25.
The Chlor-Alkali segment was left alone. The company confirmed sales of EUR 320 million to EUR 400 million, against EUR 387 million in 2024/25, and EBIT of EUR 45 million to EUR 65 million, against EUR 58 million.
Analysis: the guidance cut separates the two businesses
Read as a single line, the announcement looks like a company lowering its outlook. Read segment by segment, it is narrower than that. Every euro of the EBIT revision sits in Green Hydrogen. Chlor-Alkali guidance was reproduced unchanged, with both its sales and its EBIT ranges bracketing the prior year figures, so the revision leaves the Chlor-Alkali segment’s stated outlook where it was. The group EBIT range moved by EUR 25 million at the bottom end and EUR 45 million at the top, which is close to the EUR 30 million of one-off charges plus the effect of shifting the Green Hydrogen sales range down by roughly EUR 20 million to EUR 40 million.
The arithmetic of the SOEC exit is unusually explicit for an ad-hoc release. A one-time cost of approximately EUR 30 million buys an annual EBIT improvement of up to EUR 10 million and about EUR 20 million of cash flow. On the earnings measure alone that is a payback of roughly three years, and on cash a payback inside two. The company describes the decision as a realignment of its SOEC activities. What the release does not establish is how much of the up to EUR 10 million is genuinely recurring. The guidance says up to EUR 10 million rather than a fixed figure, and the saving comes from stopping spending rather than from selling anything, so the figure depends on how much SOEC development the company continues outside its own manufacturing capacity.
The order intake line is the part a reader should sit with longest. The day after the ad-hoc release, on 12 August 2026, thyssenkrupp nucera published a press release under the headline “thyssenkrupp nucera Doubles Order Intake in the First Nine Months of 2025/2026”. Nine month order intake rising sharply while the full year ceiling comes down from EUR 850 million to EUR 670 million is consistent, on GSN’s reading of the two figures, with the top of the old range resting on specific contracts expected in the final quarter rather than on a general run rate. The bottom of the range, EUR 550 million, did not move, and even that is well above the EUR 348 million booked in 2024/25.
The sales guidance carries the opposite signal. Group sales of EUR 450 million to EUR 500 million against EUR 845 million a year earlier is a decline of more than 40 percent at the midpoint, and the Green Hydrogen decline from EUR 459 million to EUR 100 million to EUR 130 million accounts for nearly all of it. Order intake and revenue are moving in opposite directions because plant projects convert to revenue over years. A careful reader would take the order figure as the leading indicator and the revenue figure as the record of what was ordered two or three years ago, when green hydrogen final investment decisions in Europe were scarce.
The disclosure framework
The release was made under Article 17 of the Market Abuse Regulation, which requires an issuer to inform the public as soon as possible of inside information which directly concerns that issuer. That obligation is what puts a strategic decision of this kind into the market at 18:59 on a Tuesday rather than at the next quarterly presentation. The same regulation permits a delay in disclosure in defined circumstances, and requires immediate disclosure if confidentiality is no longer ensured.
Separately, Directive 2004/109/EC obliges issuers of shares admitted to trading on a regulated market to publish a half-yearly financial report as soon as possible after the end of the period and at the latest two months thereafter, and to keep it available to the public for at least five years. thyssenkrupp nucera reports on a financial year that does not end in December, so its half-yearly report for 2025/26 was published in May 2026, and the fourth quarter in which the SOEC charges fall is the quarter that closes the year.
What to watch in the annual figures
The company pointed readers to pages 31 to 32 of its 2024/25 annual report for definitions of the performance indicators it uses, a detail that matters because the guidance ranges are stated on EBIT rather than on a reported operating profit line. Three things in the full year figures will test the August statement: whether the one-off charge comes in at approximately EUR 30 million or above it, whether Chlor-Alkali EBIT lands inside the confirmed EUR 45 million to EUR 65 million band, and where order intake finishes within the EUR 550 million to EUR 670 million range. The last of those is the only one of the three that the company did not fix by decision.
